« Return to News | R&D Trends

Janssen, J&J Innovation ally with The Icahn School Of Medicine at Mount Sinai

Wednesday, July 3, 2013 12:30 PM

Janssen Biotech and Johnson & Johnson Innovation have established a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease (IBD) and the discovery of next generation therapeutic solutions.

Scientists from the Janssen Immunology Therapeutic Area and researchers from Mount Sinai will investigate disease triggers, identify new opportunities for therapeutic interventions and establish diagnostics to facilitate precision medicine and predictive biomarkers.

"Research alliances such as these allow us to develop, patent, license and translate laboratory breakthroughs into clinical applications," said Dennis Charney, M.D., Anne and Joel Ehrenkranz dean at Mount Sinai and executive vice president for academic affairs.

The collaboration will focus on building a Molecular Interaction Network of Disease (MIND) in IBD with the breadth and depth to yield therapeutic hypotheses to be tested in vitro and in vivo. Using preclinical models, clinical study data and patient samples, researchers, computational biologists and translational medicine scientists will develop clinical methodologies to test hypotheses and identify potential therapeutic candidates.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.